


US Pharma Windlas LLC
Standalone Balance Sheet as at March 31, 2019

Particulars	Note No.	IN R - Thousands	
		As at	
		March 31, 2019	
ASSETS:			
Non-Current Assets:			
Property, Plant and Equipment	3	-	
Capital work-in-progress		-	
Goodwill		-	
Other Intangible Assets	3	-	
Intangible Assets Under Development	3	-	
Financial Assets:			
Investments	4	-	
Loans	5	-	
Other Financial Assets	6	-	
Deferred Tax Assets [Net]	21	-	
Other Non-Current Assets	7	-	
Assets for Current tax [Net]	8	-	
Current Assets:			
Inventories	9	-	
Financial Assets:			
Investments	10	-	
Trade Receivables	11	-	
Cash and Cash Equivalents	12	7,175.41	
Bank Balance other than above	12	-	
Loans	13	-	
Other Current Financial Assets	14	-	
Other Current Assets	15	-	
Assets classified as held for sale	45	7,175.41	
Total		7,175.41	
EQUITY AND LIABILITIES:			
Equity:			
Share Capital	16	692.80	
Other Equity	17	3,605.21	
		4,298.01	
Non-Current Liabilities:			
Financial Liabilities:			
Borrowings	18	-	
Other Financial Liabilities	19	-	
Provisions	20	-	
Deferred Tax Liabilities [Net]	21	-	
Current Liabilities:			
Financial Liabilities:			
Borrowings			
Trade Payables	22	-	
(a) total outstanding dues of micro enterprises and small enterprises	23	-	
(b) total outstanding dues for creditors other than micro enterprises and small enterprises		-	
Other Financial Liabilities	24	2,775.20	
Other Current Liabilities	25	102.20	
Provisions	26	-	
Current Tax Liabilities [Net]	27	-	
Total		2,877.40	
Significant Accounting Policies		7,175.41	
Notes to the Financial Statements	2		
	1 to 49		


For and on behalf of the board


Kailash Badoni
 CFO

US Pharma Windlas LLC
Unaudited Standalone Statement of Profit and Loss for the period ended March 31, 2019

Particulars	Note No.	INR - Thousands
		Year ended March 2019 (Unaudited)
Revenue from Operations	30	13,688.62
Other Income		
Total Income	31	8.43
EXPENSES:		13,697.05
Cost of Materials Consumed	32	-
Purchases of Stock-in-Trade	33	-
Changes in Inventories of Finished goods, Work-in-progress and Stock-in-Trade	34	-
Excise Duty on Sales		-
Employee Benefits Expense	35	-
Finance Costs	36	-
Depreciation, Amortisation and Impairment expense	3	-
Other Expenses		-
Total Expenses	37	13,164.86
Profit before Tax		13,164.86
Less: Tax Expense:		532.19
Current Tax	38	-
Deferred Tax	38	-
Profit for the year		532.19
OTHER COMPREHENSIVE INCOME [OCI]:		
Items that will not be reclassified to profit or loss:		
Re-measurement losses on post employment defined benefit plans		-
Income tax effect		-
Net Loss/ [Gain] on Fair Value through OCI [FVTOCI] Equity Securities		-
Income tax effect		-
Other Comprehensive Income for the year [Net of tax]		-
Total Comprehensive Income for the year [Net of Tax]		-
Basic & Diluted Earning per Equity Share(EPS)		532.19

For and on behalf of the board


 Kailash Badoni <
 CFO

US Pharma Windlas LLC
Notes to the Financial Statements

			INR - Thousands
	Face Value	Nos.	As at
			March 31, 2019
Note: 4-Investments [Non-Current]:			
Investments in Subsidiaries and Joint Ventures:			-
Investments - Others:			-
Investments in Equity Instruments			-
Less: Impairment Allowances			-
Total			-
Note: 5-Loans:			
[Unsecured, Considered Good unless otherwise stated]			-
Security Deposits			-
Total			-
Note: 6-Other Financial Assets:			
[Unsecured, Considered Good unless otherwise stated]			-
Security Deposits			-
Forward Contract value related to investment in a Joint Venture			-
Bank Balance (FD)			-
Others			-
Total			-
Note: 7-Other Non-Current Assets:			
[Unsecured, Considered Good unless otherwise stated]			-
Capital Advances			-
Less: Impairment Allowances			-
Balances with Statutory Authorities			-
Others			-
Total			-
Note: 8-Current Tax Assets [Net]:			
Advance payment of Tax			-
Total			-
Note: 9-Inventories:			
[The Inventory is valued at lower of cost and net realisable value]			-
Classification of Inventories:			
	Raw Materials		-
	Work-in-progress		-
	Finished Goods		-
	Stock-in-Trade		-
	Stores and Spares		-
Others:			
	Packing Materials		-
Total			-
The above includes Goods in transit as under:			
	Raw Materials		-
	Stock-in-Trade		-
	Packing Materials		-
Amount recognised as an expense in statement of profit and loss resulting from write-down of inventories			-
	Net of reversal of write-down		-
For details of inventories pledged as security, refer Note 21.			-

US Pharma Windlas LLC
Notes to the Financial Statements

Note: 10-Investments [Current]:		As at
		March 31, 2019
	Nos.	
Investments in Government Securities [Unquoted] [Valued at amortised cost]		-
Investment in Mutual Funds [Quoted]	0	-
Total		-
Note: 11-Trade Receivables:		March 31, 2019
Secured - Considered good		-
Unsecured - Considered good		-
Unsecured - Considered doubtful		-
Less: Impairment allowances		-
Total		-
Note: 12-Cash and Cash Equivalents:		March 31, 2019
Balances with Banks [*]		7,175
Sweep in Deposit with Bank		-
Cash on Hand		-
Total		7,175
Note: 12.1-(Bank Balance Other than above		
Fixed Deposit		-
Total		-
Note: 13-Loans:		March 31, 2019
[Unsecured, Considered Good]		
Loans and advances to related parties [*]		-
Investments in Current Capital of a Partnership Firm		-
Others		-
Total		-
Note: 14-Other Current Financial Assets:		March 31, 2019
[Unsecured, Considered Good]		
Forward Contract value related to investment in a Joint Venture		-
Dividend Receivable		-
Rent Receivable		-
Other Current Financial Assets		-
Other advances		-
Total		-
Note: 15-Other Current Assets:		March 31, 2019
[Unsecured, Considered Good]		
Balances with Statutory Authorities		-
Advances to Suppliers		-
Less: Impairment allowance		-
Export Incentive Receivables		-
Prepaid Expenses		-
Other		-
Total		-
Note: 16-Equity Share Capital:		March 31, 2019
Issued, Subscribed and Paid-up:		
Authorised Shares		
10,000 (Previous Year 10,000) Equity Shares of \$1 each (Previous Year of \$ 1 each)		693
10,000 (Previous Year 10,000) Equity Shares of \$1 each (Previous Year of \$ 1 each)		-
Issued, Subscribed & Fully Paid up Shares		693
10,000 (Previous Year 10,000) Equity Shares of \$1 each (Previous Year of \$ 1 each)		693
Total subscribed and fully paid up share capital		693



Notes to the Financial Statements

		March 31, 2019
Note: 17-Other Equity:		
Other Reserves:		
Capital Reserve	Balance as per last Balance Sheet	-
Security Premium	Balance as per last Balance Sheet	-
Equity Component of Convertible Preference Shares		
Retained Earnings:		
	Balance as per last Balance Sheet	3,073
	Add: Profit for the period	532
	Balance as at the end of the year	3,605
Total		3,605

	Non-current portion		Current Maturities	
	March 31, 2019	March 31, 2020	March 31, 2019	March 31, 2019
Note: 18-Borrowings:				
As at				
A				
Term Loans from Banks:				
a	Secured	-	-	-
b	Unsecured	-	-	-
Term Loans from Banks:				
a	Secured	-	-	-
b	Unsecured	-	-	-
Non Convertible Debenture				
a	Secured	-	-	-
b	Unsecured	-	-	-
From Others [Unsecured]				
Total	B	-	-	-
<p>The above amount includes:</p> <p>Secured borrowings</p> <p>Unsecured borrowings</p> <p>Amount disclosed under the head "Other Current Financial Liabilities" [Note-24]</p>				
Net amount				

Note: 20-Provisions:		March 31, 2019
Provision for Employee Benefits		-
Total		-

Note: 22-Borrowings: Loans repayable on Demand: March 31, 2019

Working Capital Loans from Banks [Secured] [*]
Working Capital Loans from Banks [Unsecured] [**]

Note: 23-Trade Payables: March 31, 2019

Micro, Small and Medium Enterprises [*]
Others
Total

Note: 24-Other Financial Liabilities: March 31, 2019

Current Maturities of Long Term Debt [Refer Note- 18]
Interest accrued but not due on borrowings
Book Overdraft
Accrued Expenses
Payable for Capital Goods
Unpaid Dividends [*]
Others
Total

Note: 25-Other Current Liabilities: March 31, 2019

Advances from Customers
Payable to Statutory Authorities
Others
Total

US Pharma Windlas LLC
Notes to the Financial Statements

	INR - Thousands
	For the period Ended
	March 31, 2019
Note: 30-Revenue from Operations:	
Sale of Products	-
Other Operating Revenues:	
Share of Profit from a Partnership Firm	-
Royalty Income	-
Net Gain on foreign currency transactions and translation [*]	235.39
Export Incentives	-
Government Grants	-
Dossier License Fees	-
Sale of services	13,453.23
Total	13,688.62
	13,688.62
[*] includes research related Net Loss on foreign currency transactions and translation	-
Note: 31-Other Income:	
	March 31, 2019
Finance Income:	
Interest Income on Financial Assets measured at Amortised Cost	8.43
Gain on valuation of Forward Contract value related to investment in a Joint Venture	-
	8.43
Dividend Income:	
From FVTOCI Investments	-
From Other Investments [*]	-
	-
Gain on Investments measured at FVTPL	-
Miscellaneous Income	-
Gain On conversion of OCPS into Equity	-
Other Non-operating Income	-
Total	8.43
	8.43
[*] Includes dividend from subsidiary companies	-
Note: 32-Cost of Materials Consumed:	
	March 31, 2019
Raw Materials [Pharmaceutical Ingredients]:	
Stock at commencement	-
Adjusted due to de-merger [Refer Note- 49]	-
Add Purchases	-
	-
Less: Stock at close	-
	-
Packing Materials consumed	-
Total	-
	-
Note: 33-Purchases of Stock-in-Trade:	
	March 31, 2019
Purchases of Stock-in-Trade	-
Total	-
	-
Note: 34-Changes in Inventories:	
	March 31, 2019
Stock at commencement:	
Work-in-progress	-
Work-in-progress adjusted due to de-merger [Refer Note- 49]	-
Finished Goods	-
Finished Goods adjusted due to de-merger [Refer Note- 49]	-
Stock-in-Trade	-
Stock-in-Trade adjusted due to de-merger [Refer Note- 49]	-
	-
Less: Stock at close:	
Work-in-progress	-
Finished Goods	-
Stock-in-Trade	-
	-
	-
Differential Excise Duty on Opening and Closing stock of Finished Goods	-
Total	-
	-

US Pharma Windlas LLC
Notes to the Financial Statements

		March 31, 2019
Note: 35-Employee Benefits Expense:		
Salaries and wages*		-
Contribution to provident and other funds [*]		-
Staff welfare expenses		-
Total		-

		March 31, 2019
Note: 36-Finance Cost:		
Interest expense [*]		-
Other Borrowing Costs		-
Net [Gain]/ Loss on foreign currency transactions and translation		-
Bank commission & charges		-
Total		-
[*] The break up of interest expense into major heads is given below:		
On term loans		-
On working capital loans		-
Others		-
Total		-

		March 31, 2019
Note: 37-Other Expenses:		
Research Materials		-
Analytical Expenses		-
Consumption of Stores and spare parts		-
Power & fuel		-
Rent [*]		-
Repairs to Buildings		-
Repairs to Plant and Machinery		-
Repairs to Others		-
Insurance		-
Rates and Taxes [excluding taxes on income]		-
Processing Charges		-
Managing Directors' Remuneration		-
Commission to Directors		-
Traveling Expenses		-
Legal and Professional Fees		-
Payment to Auditors		13,019.34
- As statutory auditor		-
- For other certifications		-
Net Loss on foreign currency transactions and translation		-
Commission on sales		-
Freight and forwarding on sales		-
Representative Allowances		-
Other marketing expenses		-
Bad Debts:		-
Bad debts written off		-
Impairment allowances		-
Less: Transferred from impairment allowances		-
Doubtful Advances:		-
Doubtful advances written off		-
Impairment allowances		-
Less: Transferred from impairment allowances		-
Directors' fees		-
Other provisions		-
Donations [**]		-
Interest on delayed payments		-
Other Administrative Expenses		-
Other Bank charges		-
Other Research Expenses		-
Miscellaneous Expenses [***]		-
Total		145.52
Less: Recovery of expenses towards Cost Allocation Charges [Refer Note: 35 {**}]		13,164.86
Total		13,164.86

